Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(5):703–709. doi: 10.1038/bjc.1997.125

Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.

G J Veldhuis 1, P H Willemse 1, J H Beijnen 1, H Boonstra 1, H Piersma 1, W T van der Graaf 1, E G de Vries 1
PMCID: PMC2063352  PMID: 9043028

Abstract

The tolerability and efficacy of four courses of paclitaxel and ifosfamide plus cisplatin every 3 weeks was evaluated in patients with residual or refractory ovarian cancer. Additionally, supportive haematological effects of recombinant human interleukin 3 (rhIL-3) and recombinant human granulocyte colony-stimulating factor (G-CSF) were studied. Paclitaxel starting dose was 135 mg m(-2) (day 1), with ifosfamide dose 1.2 g m(-2) day(-1) (days 2-4) and cisplatin dose 30 mg m(-2) day(-1) (days 2-4). All 16 patients received 5.0 microg kg(-1) day(-1) G-CSF (days 7-16) and, in addition, eight patients were randomized to receive 10 microg kg(-1) day(-1) rhIL-3 (days 5-9). Paclitaxel and ifosfamide doses were reduced when grade IV haematological toxicity occurred. In the absence of grade IV haematological toxicity and normal recovery of haematopoiesis, paclitaxel dose was escalated. Toxicity was evaluable in 56 courses, with haematological effects in 52. Despite antiemetic treatment, nausea and vomiting (> or = grade I) occurred in 50 courses. Five patients had persisting peripheral neuropathy. Renal and liver function were not affected. Grade IV neutropenia occurred in 12 out of 52 courses, with neutropenic fever in two patients, both of whom died from fatal septicaemia. Grade IV thrombocytopenia without bleeding was observed in 15 courses. Grade IV haematological toxicity was associated with hepatic metastases and concurrent increases in alkaline phosphatase (P <0.001) and gamma-glutamyltransferase (P=0.007). No relation was found between haematological toxicity and pharmacokinetic parameters of paclitaxel. Patients treated with rhIL-3 showed a tendency to a faster platelet recovery (not affecting platelet nadir), and the cisplatin dose intensity was higher (P=0.025). Six of the nine evaluable patients had a tumour response. The overall median progression-free survival was 7 months and the overall mean survival was 13 months. In conclusion, this potentially interesting combination as second-line treatment showed a low tolerability with unexpected mortality, while rhIL-3 administration tended to induce a more rapid platelet recovery.

Full text

PDF
703

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Biesma B., Pokorny R., Kovarik J. M., Duffy F. A., Willemse P. H., Mulder N. H., de Vries E. G. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer. Cancer Res. 1993 Dec 15;53(24):5915–5919. [PubMed] [Google Scholar]
  2. Biesma B., Willemse P. H., Mulder N. H., Sleijfer D. T., Gietema J. A., Mull R., Limburg P. C., Bouma J., Vellenga E., de Vries E. G. Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood. 1992 Sep 1;80(5):1141–1148. [PubMed] [Google Scholar]
  3. Bruno E., Briddell R., Hoffman R. Effect of recombinant and purified hematopoietic growth factors on human megakaryocyte colony formation. Exp Hematol. 1988 Jun;16(5):371–377. [PubMed] [Google Scholar]
  4. Cersosimo R. J. Cisplatin neurotoxicity. Cancer Treat Rev. 1989 Dec;16(4):195–211. doi: 10.1016/0305-7372(89)90041-8. [DOI] [PubMed] [Google Scholar]
  5. D'Hondt V., Weynants P., Humblet Y., Guillaume T., Canon J. L., Beauduin M., Duprez P., Longueville J., Müll R., Chatelain C. Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study. J Clin Oncol. 1993 Nov;11(11):2063–2071. doi: 10.1200/JCO.1993.11.11.2063. [DOI] [PubMed] [Google Scholar]
  6. Einzig A. I., Wiernik P. H., Sasloff J., Runowicz C. D., Goldberg G. L. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol. 1992 Nov;10(11):1748–1753. doi: 10.1200/JCO.1992.10.11.1748. [DOI] [PubMed] [Google Scholar]
  7. Eisenhauer E. A., ten Bokkel Huinink W. W., Swenerton K. D., Gianni L., Myles J., van der Burg M. E., Kerr I., Vermorken J. B., Buser K., Colombo N. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994 Dec;12(12):2654–2666. doi: 10.1200/JCO.1994.12.12.2654. [DOI] [PubMed] [Google Scholar]
  8. Gore M. E., Preston N., A'Hern R. P., Hill C., Mitchell P., Chang J., Nicolson M. Platinum-Taxol non-cross resistance in epithelial ovarian cancer. Br J Cancer. 1995 Jun;71(6):1308–1310. doi: 10.1038/bjc.1995.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Huizing M. T., Keung A. C., Rosing H., van der Kuij V., ten Bokkel Huinink W. W., Mandjes I. M., Dubbelman A. C., Pinedo H. M., Beijnen J. H. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol. 1993 Nov;11(11):2127–2135. doi: 10.1200/JCO.1993.11.11.2127. [DOI] [PubMed] [Google Scholar]
  10. Huizing M. T., Vermorken J. B., Rosing H., ten Bokkel Huinink W. W., Mandjes I., Pinedo H. M., Beijnen J. H. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol. 1995 Sep;6(7):699–704. doi: 10.1093/oxfordjournals.annonc.a059287. [DOI] [PubMed] [Google Scholar]
  11. Jekunen A. P., Christen R. D., Shalinsky D. R., Howell S. B. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer. 1994 Feb;69(2):299–306. doi: 10.1038/bjc.1994.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kelland L. R., Abel G. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol. 1992;30(6):444–450. doi: 10.1007/BF00685595. [DOI] [PubMed] [Google Scholar]
  13. Kohn E. C., Sarosy G., Bicher A., Link C., Christian M., Steinberg S. M., Rothenberg M., Adamo D. O., Davis P., Ognibene F. P. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst. 1994 Jan 5;86(1):18–24. doi: 10.1093/jnci/86.1.18. [DOI] [PubMed] [Google Scholar]
  14. Lu L., Briddell R. A., Graham C. D., Brandt J. E., Bruno E., Hoffman R. Effect of recombinant and purified human haematopoietic growth factors on in vitro colony formation by enriched populations of human megakaryocyte progenitor cells. Br J Haematol. 1988 Oct;70(2):149–156. doi: 10.1111/j.1365-2141.1988.tb02456.x. [DOI] [PubMed] [Google Scholar]
  15. Markman M., Hakes T., Reichman B., Lewis J. L., Jr, Rubin S., Jones W., Almadrones L., Pizzuto F., Hoskins W. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol. 1992 Feb;10(2):243–248. doi: 10.1200/JCO.1992.10.2.243. [DOI] [PubMed] [Google Scholar]
  16. McGuire W. P., Hoskins W. J., Brady M. F., Kucera P. R., Partridge E. E., Look K. Y., Clarke-Pearson D. L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 4;334(1):1–6. doi: 10.1056/NEJM199601043340101. [DOI] [PubMed] [Google Scholar]
  17. McGuire W. P., Rowinsky E. K., Rosenshein N. B., Grumbine F. C., Ettinger D. S., Armstrong D. K., Donehower R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989 Aug 15;111(4):273–279. doi: 10.7326/0003-4819-111-4-273. [DOI] [PubMed] [Google Scholar]
  18. Ottmann O. G., Abboud M., Welte K., Souza L. M., Pelus L. M. Stimulation of human hematopoietic progenitor cell proliferation and differentiation by recombinant human interleukin 3. Comparison and interactions with recombinant human granulocyte-macrophage and granulocyte colony-stimulating factors. Exp Hematol. 1989 Feb;17(2):191–197. [PubMed] [Google Scholar]
  19. Postmus P. E., Gietema J. A., Damsma O., Biesma B., Limburg P. C., Vellenga E., de Vries E. G. Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study. J Clin Oncol. 1992 Jul;10(7):1131–1140. doi: 10.1200/JCO.1992.10.7.1131. [DOI] [PubMed] [Google Scholar]
  20. Proost J. H., Meijer D. K. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med. 1992 May;22(3):155–163. doi: 10.1016/0010-4825(92)90011-b. [DOI] [PubMed] [Google Scholar]
  21. Rowinsky E. K., Gilbert M. R., McGuire W. P., Noe D. A., Grochow L. B., Forastiere A. A., Ettinger D. S., Lubejko B. G., Clark B., Sartorius S. E. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol. 1991 Sep;9(9):1692–1703. doi: 10.1200/JCO.1991.9.9.1692. [DOI] [PubMed] [Google Scholar]
  22. Sarosy G., Kohn E., Stone D. A., Rothenberg M., Jacob J., Adamo D. O., Ognibene F. P., Cunnion R. E., Reed E. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol. 1992 Jul;10(7):1165–1170. doi: 10.1200/JCO.1992.10.7.1165. [DOI] [PubMed] [Google Scholar]
  23. Schiller J. H., Storer B., Tutsch K., Arzoomanian R., Alberti D., Feierabend C., Spriggs D. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol. 1994 Feb;12(2):241–248. doi: 10.1200/JCO.1994.12.2.241. [DOI] [PubMed] [Google Scholar]
  24. Sevelda P., Mayerhofer K., Obermair A., Stolzlechner J., Kurz C. Thrombosis with paclitaxel. Lancet. 1994 Mar 19;343(8899):727–727. doi: 10.1016/s0140-6736(94)91602-0. [DOI] [PubMed] [Google Scholar]
  25. Sutton G. P., Blessing J. A., Homesley H. D., Berman M. L., Malfetano J. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1989 Nov;7(11):1672–1676. doi: 10.1200/JCO.1989.7.11.1672. [DOI] [PubMed] [Google Scholar]
  26. Takaue Y., Kawano Y., Reading C. L., Watanabe T., Abe T., Ninomiya T., Shimizu E., Ogura T., Kuroda Y., Yokobayashi A. Effects of recombinant human G-CSF, GM-CSF, IL-3, and IL-1 alpha on the growth of purified human peripheral blood progenitors. Blood. 1990 Jul 15;76(2):330–335. [PubMed] [Google Scholar]
  27. Teramura M., Katahira J., Hoshino S., Motoji T., Oshimi K., Mizoguchi H. Clonal growth of human megakaryocyte progenitors in serum-free cultures: effect of recombinant human interleukin 3. Exp Hematol. 1988 Nov;16(10):843–848. [PubMed] [Google Scholar]
  28. Theodossiou C., Kroog G., Ettinghausen S., Tolcher A., Cowan K., O'Shaughnessy J. Acute arterial thrombosis in a patient with breast cancer after chemotherapy with 5-fluorouracil, doxorubicin, leucovorin, cyclophosphamide, and interleukin-3. Cancer. 1994 Nov 15;74(10):2808–2810. doi: 10.1002/1097-0142(19941115)74:10<2808::aid-cncr2820741011>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  29. Thigpen J. T., Blessing J. A., Ball H., Hummel S. J., Barrett R. J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol. 1994 Sep;12(9):1748–1753. doi: 10.1200/JCO.1994.12.9.1748. [DOI] [PubMed] [Google Scholar]
  30. Trimble E. L., Adams J. D., Vena D., Hawkins M. J., Friedman M. A., Fisherman J. S., Christian M. C., Canetta R., Onetto N., Hayn R. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol. 1993 Dec;11(12):2405–2410. doi: 10.1200/JCO.1993.11.12.2405. [DOI] [PubMed] [Google Scholar]
  31. Untch M., Sevin B. U., Perras J. P., Angioli R., Untch A., Hightower R. D., Koechli O., Averette H. E. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay. Gynecol Oncol. 1994 Apr;53(1):44–49. doi: 10.1006/gyno.1994.1085. [DOI] [PubMed] [Google Scholar]
  32. Vanhoefer U., Harstrick A., Wilke H., Schleucher N., Walles H., Schröder J., Seeber S. Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer. 1995;31A(1):92–97. doi: 10.1016/0959-8049(94)00440-g. [DOI] [PubMed] [Google Scholar]
  33. Veldhuis G. J., Willemse P. H., van Gameren M. M., Aalders J. G., Mulder N. H., Mull B., Biesma B., de Vries E. G. Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial. J Clin Oncol. 1995 Mar;13(3):733–740. doi: 10.1200/JCO.1995.13.3.733. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES